Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

April 3, 2018

Primary Completion Date

March 18, 2025

Study Completion Date

March 18, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

CC-93269

Specified dose on specified days

Trial Locations (34)

8035

Local Institution - 208, Barcelona

10019

Icahn School of Medicine at Mount Sinai Mount Sinai West, New York

20089

Local Institution - 401, Milan

20246

Local Institution - 303, Hamburg

24127

Local Institution - 402, Bergamo

28007

Local Institution - 205, Madrid

30322

Local Institution - 106, Atlanta

31008

Local Institution - 201, Pamplona

35294

Local Institution - 105, Birmingham

37007

Local Institution - 203, Salamanca

39008

Local Institution - 204, Santander

46009

Local Institution - 207, Valencia

46017

Local Institution - 202, Valencia

47014

Local Institution - 403, Meldola

48202

Henry Ford Medical Center - New Center One, Detroit

69120

Local Institution - 302, Heidelberg

72076

Local Institution - 304, Tübingen

75158

Local Institution - 505, Uppsala

81675

Local Institution - 306, München

91054

Local Institution - 305, Erlangen

94143

Local Institution - 103, San Francisco

98104

Local Institution - 101, Seattle

1508935

Local Institution - 603, Shibuya-ku

4678602

Local Institution - 602, Nagoya

06510

Local Institution - 107, New Haven

02114

Local Institution - 109, Boston

02215

Local Institution - 111, Boston

247-8533

Local Institution - 605, Kamakura

277-8577

Local Institution - 604, Kashiwa

602-8566

Local Institution - 601, Kyoto

08916

Local Institution - 206, Barcelona

413 46

Local Institution - 504, Gothenborg

SE-221 85

Local Institution - 502, Lund

141 86

Local Institution - 501, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY